Despite the higher levels of CXCL10 and CXCL13 in AOSD than RA and healthy donors and the confirmed potential role of CXCL9, CXCL10 and CXCL13 as clinical biomarkers for disease activity in AOSD [47,48], our analysis showed no difference between concentrations of these CXC chemokine ligands before and after canakinumab treatment. The gene discussed is CXCL10; the disease is rheumatoid arthritis.